ALT Altimmune, Inc.

Healthcare [ 3/11 ] | Biotechnology [ 34/154 ]

US | NASDAQ | Stock

Price: $15.16

Increased by +0.80%
Dollar Volume: 18.99 M
ADR%: 7.15
Earnings Report Date (estimate): Mar 13, 23 (-0.51)

Market Cap.: 745.25 M
Shares Float: 40.06 M
Shares Outstanding: 49.16 M

Beta: 0.19
Price / Earnings: -6.35
BPR: 434.11

20D Range: 12.30 17.17
50D Range: 8.29 17.17
200D Range: 3.83 23.48

Quarterly Earnings
Annual Earnings

Reported Date	EPSChange YoY	EstimateSurprise
Nov 10, 22	-0.48 Increased by +40.74%	-0.50 Increased by +4.00%
Aug 11, 22	-0.42 Increased by +30.00%	-0.47 Increased by +10.64%
May 12, 22	-0.44 Decreased by -15.79%	-0.58 Increased by +24.14%
Mar 15, 22	-0.57 Decreased by -235.29%	-0.65 Increased by +12.31%
Nov 9, 21	-0.81 Decreased by -50.00%	-0.39 Decreased by -107.69%
Aug 10, 21	-0.60 Increased by +36.17%	-0.50 Decreased by -20.00%
May 17, 21	-0.38 Decreased by -46.15%	-0.47 Increased by +19.15%
Feb 25, 21	-0.17 Increased by +32.00%	-0.75 Increased by +77.33%

Quarterly Financials
Annual Financials

Fiscal ending date	RevenueChange YoY	IncomeChange YoY	ProfitChange YoY
Sep 30, 22	2.00 K Decreased by -98.73%	-23.52 M Increased by +29.83%	Decreased by -1.18 M% Decreased by -5.43 K%
Jun 30, 22	8.00 K Decreased by -94.19%	-20.11 M Increased by +19.01%	Decreased by -251.34 K% Decreased by -1.29 K%
Mar 31, 22	32.00 K Decreased by -96.18%	-19.43 M Decreased by -30.72%	Decreased by -60.72 K% Decreased by -3.32 K%
Dec 31, 21	-1.13 M Decreased by -148.79%	73.10 M Increased by +788.25%	Decreased by -6.48 K% Decreased by -1.31 K%
Sep 30, 21	157.56 K Decreased by -94.64%	-33.51 M Decreased by -88.58%	Decreased by -21.27 K% Decreased by -3.42 K%
Jun 30, 21	137.62 K Decreased by -80.93%	-24.83 M Decreased by -48.07%	Decreased by -18.04 K% Decreased by -676.41%
Mar 31, 21	837.52 K Decreased by -62.15%	-14.86 M Decreased by -282.54%	Decreased by -1.77 K% Decreased by -910.66%
Dec 31, 20	2.31 M Increased by +301.65%	-10.62 M Decreased by -159.28%	Decreased by -459.28% Increased by +35.45%

Top 20 ETF Stock Exposure
Top 20 Institutional Holders
Top 20 Mutual Fund Holders

Rank	ETF	Shares	Market Value	Weight % in ETF

DAILY

WEEKLY

MONTHLY

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.